Treatment with anti-cFLIP mediators in combination with anticancer agents such as doxorubicin, cisplatin, and taxol has been shown to reduce the levels of c-FLIP and sensitize cells to chemotherapeutic-mediated apoptosis in human glioma, melanoma, prostate, leukemic, and breast cancer cell lines, demonstrating the potential of c-FLIP as a therapeutic target in ovarian cancer [143,144,145]. This evidence concerns the gene CFLAR and breast cancer.